Today’s has my column on the pharma is facing in China. One of the earliest industries to see the need to sell into the domestic Chinese market (versus seeing China as a source of low-cost production), pharma is also one of the most dynamic sectors in China.
Some of the challenges pharma faces are to be expected: the impact of price controls for the highest volume drugs, managing the still in flux payer system, and protecting intellectual property. But some of the opportunities pharma is finding in China are not obvious, in particular, how American and European pharma is accessing China as a .
As always, comments and thoughts are welcome. The column can be read .
About the Author
Benjamin
Ben is the Founder and Managing Director of Rubicon Strategy Group, a consulting firm specializing in helping American and European companies enter emerging markets. He is a member of the National Committee on US-China Relations and holds an advisory board seat at Indiana University’s Research Center on Chinese Politics and Business. He is a columnist for the Asia Times on US-China trade and economic policy matters, with a particular focus on how relations between the two countries are being impacted post the 2008 financial crisis.
As a founder of the consulting firm Teleos, he was an early advocate for Chinese companies moving away from cost-only business models towards ones that emphasized brand building, innovation and product development. He founded Teleos Healthcare which licensed, capitalized and commercialized the IP for an OTC medical appliance used to help stop nosebleeds. This company successfully partnered with a major US pharmaceutical company on the product launch for the hemophilia and VWD bleeding disorder community. In addition, Ben has successfully managed projects in China across a number of industries, ranging from consumer goods to more complex engineered products.
He holds his MBA from Duke University in Durham, North Carolina.
Great column Ben. Few sectors show so much promise and so many obstacles in China. Truly, everything is possible but nothing is easy.